Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Isicom vs Nacom (Levodopa/Carbidopa) in Healthy Volunteers
NCT02116465Phase 1Completed
- Sponsor
- Desitin Arzneimittel
- Start
- Mar 2014
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of levodopa and carbidopa in Parkinson's disease (PD) (4 arms), sponsored by Desitin Arzneimittel. Primary endpoints: Maximum Plasma Concentration at 12 hours and Area Under the Curve at 12 hours. Started Mar 2014; status: completed.
02
Drugs
levodopacarbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02116465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02116465.